Search | Clinical Trials Finder

Conditions: Wound Heal, Venous Leg Ulcer
Interventions: InnovaMatrix® AC; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: North Port, Florida

Conditions: Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions: All sentinel cohort participants will receive biologic plus SOC. who receive at least one treatment of the biologic plus SOC and complete the treatment period of 12 weeks., Standard wound care for diabetic foot ulcers, Participants in the randomized phase are assigned by randomization (2:1) to BIOxHEAL plus SOC or SOC alone. once weekly for up to 12 weeks or until complete ulcer closure; Biological · Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions: Allograft; Other
Lead sponsor: Tides Medical; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Fresno, California • Los Angeles, California • Vista, California + 5 more

Conditions: Wound of Skin
Interventions: MIST Therapy, Standard of Care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Venous Leg Ulcer
Interventions: Wound Edge Debridement, Standard of Care Treatment; Procedure · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Surgical Wound Infection, Traumatic Wound Infection
Interventions: Amicidin-β topical solution - 15 mL, Amicidin-β topical solution - 50 mL, Standard of Care (SOC); Drug
Lead sponsor: Macro Biologics, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Torrance, California • Idaho Falls, Idaho • Baltimore, Maryland + 2 more

Conditions: Wound of Skin, Wound Heal, Surgical Wound, Full Thickness Skin Graft Healing
Interventions: 0.25% timolol gel with full-thickness skin grafts, Vaseline dressing; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, Nitric Oxide Therapy 2x week 6 min. plus standard of care, Nitric Oxide Therapy 2x week 12 min. plus standard of care, Nitric Oxide Therapy 4x week 6 min. plus standard of care, Nitric Oxide Therapy 4x week 12 min. plus standard of care; Device
Lead sponsor: Origin Inc.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more

Conditions: Wounds and Injuries
Interventions: AR/101, Placebo; Drug
Lead sponsor: Arava Bio Tech Ltd.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Foot Ulcer
Interventions: AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care; Other · Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more

Conditions: Diabetic Foot Ulcers
Interventions: NEOX®CORD 1K, standard of care; Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 19
States / cities: Carlsbad, California • Castro Valley, California • Fair Oaks, California + 16 more

Conditions: Varicose Ulcer, Venous Insufficiency
Interventions: AmnioExCel dressing and compression therapy, SOC alginate dressing and compression therapy; Biological · Procedure
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Venous Leg Ulcers
Interventions: E-GRAFT ™, FIBRACOL™; Other · Device
Lead sponsor: Skye Biologics Holdings, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions: Microlyte®, IP 1: Membrane Wrap - Hydro; Device
Lead sponsor: Capsicure, LLC; Network
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 7
States / cities: San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more

Conditions: Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
Interventions: Mirragen Advanced Wound Matrix, Fibracol; Device
Lead sponsor: ETS Wound Care, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 15
States / cities: Los Angeles, California • Pomona, California • San Francisco, California + 12 more

Conditions: Diabetic Foot, Chronic Foot Ulcer, Wound Healing, Foot Ulcer
Interventions: SynPath Acellular Dermal Matrix plus Off-loading Device, Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device; Device
Lead sponsor: PolyNovo Biomaterials Pty Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Castro Valley, California • Fresno, California • Vista, California + 4 more

Conditions: Diabetic Foot Ulcer
Interventions: NuShield; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 6 more

Conditions: Venous Leg Ulcer
Interventions: Affinity; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Wound Chronic Draining, Wound Closure
Interventions: Platelet-rich fibrin (PRF); Device
Lead sponsor: Estar Medical dba Medical Technologies, LTD; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: Bradenton, Florida • San Antonio, Texas

Conditions: Skin Graft Disorder, Donor Site Complication
Interventions: Promogran Prisma, Standard of care (SOC) dressings; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Foot Ulcer
Interventions: MIST Therapy, SOC - Standard of Care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetic Foot Ulcers (DFUs)
Interventions: Meso Wound Matrix; Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Pembroke Pines, Florida • Ford City, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Radiation Dermatitis
Interventions: StrataXRT, Calendula, Aquaphor; Device · Drug
Lead sponsor: Stratpharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Wound Heal, Ulcer
Interventions: InnovaMatrix® AC; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Fresno, California • Los Angeles, California • San Diego, California + 16 more

Search by objective public record fields.

INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

Deep Tissue Injury Treatment With MIST Therapy Versus Standard Care: REVERSE DTI Study

Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers

A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections

Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

A Feasibility Study of Advance Plasma Therapy001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations

Clinical Trial Evaluating an Amnion Membrane Allograft Intended for Use in the Management of Non- Healing Venous Leg Ulcers Versus Standard Of Care Alone

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers

Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

Clinical Study Of Affinity Versus SOC In The Management Of VLUs

Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds

Impact of Prisma on Donor Site Pain

RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs

Effect of Meso Wound Matrix in the Treatment of DFUs

Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers